一种改进的方法来估计低LDL-C基于增强的桑普森-NIH方程.
Tatiana C Coverdell1, Maureen Sampson1, Rafael Zubirán2
1Clinical Center, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA.
Lipids in health and disease
|February 8, 2024
概括
一个新的增强的Sampson-NIH (eS LDL-C) 方程准确估计低密度脂蛋白胆固醇 (LDL-C) 水平. 这种改进的准确性有助于识别更多高风险心血管疾病患者,这些患者有资格接受先进的降脂疗法,如PCSK9抑制剂.
科学领域:
- 心血管医学 心血管医学
- 临床化学 临床化学
- 生物统计学 生物统计学
背景情况:
- 精确的低密度脂蛋白胆固醇 (LDL-C) 测量对于管理高风险心血管疾病 (CVD) 患者至关重要.
- 关于先进的降脂疗法的决定,如PCSK9抑制剂 (PCSK9i),取决于达到足够低的LDL-C水平,特别是当他类药物治疗不足时.
研究的目的:
- 开发和验证一个新的方程,以改善LDL-C估计.
- 新方程式将阿波利波蛋白B (apoB) 与标准脂质面板结果相结合,以提高准确性,特别是在较低的LDL-C度下.
主要方法:
- 利用β量化 (BQ) 作为一个大型失脂症队列 (N=24,406) 的参考标准.
- 使用最小平方回归分析开发了增强的Sampson-NIH (eS LDL-C) 方程.
- 使用回归参数,平均绝对差异,回归误差特征 (REC) 图形和kappa评分分析来对治疗值进行分类,评估了方程准确性.
主要成果:
- 与现有的方程 (例如,弗里德瓦尔德,桑普森-NIH,扩展的马丁) 相比,eS LDL-C 方程在广泛的 LDL-C 范围内表现出更高的准确性.
- 对于LDL-C<100 mg/dL,eS LDL-C实现了曲线下的最高面积 (0.953),并在70 mg/dL值 (kappa=0.870) 周围的患者分类方面取得了最佳表现.
- 通过Friedewald方程,eS LDL-C方程正确地重新分类了大约80%的虚假低LDL-C (<70 mg/dL) 的患者,确定了PCSK9i治疗的潜在候选人.
结论:
- 该eS LDL-C方程作为一个更准确的LDL-C确认测试.
- 它的准确性提高了对高危心血管疾病患者的识别,这些患者可能受益于先进的降脂疗法,但由于标准方程的限制,目前被错误分类.
更多相关视频
08:45LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
13.4K
11:13Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
Published on: May 9, 2019
8.8K
相关概念视频
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...